Mizuho Financial Group Inc. Sponosred ADR (Japan) vs Moderna, Inc. — how do they compare? Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $10.53 (market cap $127.85B), while Moderna, Inc. trades at $208.24 (market cap $78.65B). The key difference: Mizuho Financial Group Inc. Sponosred ADR (Japan) is the larger of the two by market cap, and Mizuho Financial Group Inc. Sponosred ADR (Japan) pays a 1.72% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mizuho Financial Group Inc. Sponosred ADR (Japan) for 0 Days and Moderna, Inc. for 59 Days on average.
| MFG | MRNA | |
|---|---|---|
Market Cap | $127.85B | $78.65B |
Volume | 3,950,750 | 37,373,437 |
Sector | Financials | Health |
52-Week High | $11.45 | $203.46 |
52-Week Low | $6.09 | $22.36 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $35.14T | $74.80B |
Dividend Yield | 1.72% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.
Read more on MFG →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →